ClinicalTrials.gg
RecruitingNCT07701733Updated Aug 14, 2026

A Study of Lung Cancer Risk

An observational study in Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
500
Ages
40 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center — 9 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
2nd of 30
500 · median 78
Started
2026
with 1 other
Observational
30 of 108
3 open now
Primary completion
2029-06
later than 18 of 19 live
Registered
108th of 108
by date

Among the 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 2nd largest by planned enrollment of the 30 observational ones that give a count, is one of 2 that started in 2026, is one of 30 observational ones, reaches primary completion later than 18 of the 19 other live ones, and was the 108th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

9 of the 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 40 Years to 74 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The researchers are doing this study to learn more about factors that may increase the risk of lung cancer in people who have never smoked. This information may help predict which people who have never smoked may be more likely to get lung cancer.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • 26-239
04

Who can participate

Ages eligible
40 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Case patients will be recruited from MSK Thoracic Surgery, Medical Oncology, and Radiation Oncology clinics. Case controls, frequency-matched for race (Asian, Black, Others, White) and age (40-49, 50-64, 65-74), will be recruited from among the 20,000 healthy women at average risk for whom screening mammography is performed annually at MSK and among women who present to the MSK Mobile Health Unit or Ralph Lauren Center for screening.

The study will also be open to interested community members who meet eligibility criteria, identified through MSK Direct, the MSK Mobile Health Unit, MSK-Medisys partnership and other community outreach, including a community-facing website.

Eligibility criteria

Criteria:

  • Female at birth
  • Age 40-74 years
  • No smoking history

    • Participants must be never-smokers, defined as having smoked \<100 cigarettes in their lifetime
  • Documentation of disease - case patients

    o Case patients must have confirmed primary lung adenocarcinoma. New and prevalent cases will be eligible. Case patients with a history of prior non-lung cancer will be eligible for the study unless actively being diagnosed or treated for another form of cancer at the time of enrollment.

  • Criteria for control participants

    • Control participants must have no personal history of lung cancer, symptoms suspicious for lung cancer, or suspicious pulmonary nodules. Participants recruited as controls and found on imaging to have lesions suspicious for lung cancer will be excluded from analysis and followed prospectively. Data regarding these participants will be reported in a sensitivity analysis. Additional control participants will be recruited to ensure balanced age- and race-matched enrollment by frequency matching. Control participants with a history of prior non-lung cancer will be eligible for the study unless actively being diagnosed or treated for another form of cancer at the time of enrollment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Case patients

    Must have pathologically confirmed primary lung adenocarcinoma.

    Other: Questionnaire

  • Control participants

    Must have no personal history of lung cancer, symptoms suspicious for lung cancer, or suspicious pulmonary nodules.

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    The study questionnaire will be administered at a regular treatment visit for case patients and at a study-specific visit for control participants. At the same visit, 1 vial of blood will be collected for genomic analysis for research purposes from both case patients and control participants. Collection of demographic information and exposure data.

06

What researchers measure

Primary outcomes

  1. Identify factors associated with the risk of NSCLC

    analyses will include all participants who completed the demographic and exposure assessment and whole-exome sequencing

    Time frame: 3 years

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact929-829-0677
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact929-829-0677
  • Memorial Sloan Kettering Bergen (All Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact929-829-0677
  • Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact929-829-0677
  • Memorial Sloan Kettering Westchester (All Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact929-829-0677
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact929-829-0677
  • Memorial Sloan Kettering Nassau (All Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact929-829-0677
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 36 months is below that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 14, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07701733
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Jun 30, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Aug 14, 2026

Study contacts

Alexis Chidi, MD, PhD
Contact
arisestudy@mskcc.org
(929) 829-0677
Tafadzwa Chaunzwa, MD
Contact
(929) 829-0677
Alexis Chidi, MD, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion